Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immuneering ( (IMRX) ) has shared an announcement.
On June 13, 2025, Immuneering Corporation held its Annual Meeting of Stockholders, where 69.1% of the company’s Class A common stock was represented. During the meeting, Ann E. Berman, Diana F. Hausman, M.D., and Thomas J. Schall, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting, and the appointment of RSM US LLP as the independent registered public accounting firm for 2025 was ratified.
The most recent analyst rating on (IMRX) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Immuneering stock, see the IMRX Stock Forecast page.
Spark’s Take on IMRX Stock
According to Spark, TipRanks’ AI Analyst, IMRX is a Underperform.
Immuneering’s stock is primarily challenged by its poor financial performance, with ongoing losses and negative cash flows posing significant risks. Technical indicators suggest bearish momentum, although the oversold RSI may hint at a potential rebound. Valuation metrics are unfavorable, highlighting persistent operational challenges and lack of profitability. The absence of significant earnings call or corporate events data limits further insights.
To see Spark’s full report on IMRX stock, click here.
More about Immuneering
Average Trading Volume: 219,057
Technical Sentiment Signal: Hold
Current Market Cap: $68.37M
Learn more about IMRX stock on TipRanks’ Stock Analysis page.